Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.67 |
| ▸ | ITGAV | P06756 | 1/20 | 0.67 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.67 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.62 |
| ▸ | ALPI | P09923 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | XIAP | P98170 | 1/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.56 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | TPH1 | P17752 | 1/20 | 0.55 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.55 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7769029 | 1.00 | ITGB3 (0.67) | ITGB3ITGAVITGA2BSLC7A5ALPI | |
| SCHEMBL19234470 | 1.00 | ITGB3 (0.67) | ITGB3ITGAVITGA2BSLC7A5ALPI | |
| SCHEMBL21690098 | 0.94 | SLC7A5 (0.62) | ITGB3ITGAVITGA2BSLC7A5ALPI | |
| SCHEMBL14381168 | 0.92 | NR1H4 (0.64) | ITGB3ITGAVITGA2BSLC7A5ALPI | |
| SCHEMBL5608045 | 0.88 | ITGB3 (0.68) | ITGB3ITGAVITGA2BSLC7A5ALPI | |
| SCHEMBL5608052 | 0.88 | ITGB3 (0.68) | ITGB3ITGAVITGA2BSLC7A5ALPI | |
| SCHEMBL6251223 | 0.87 | KMT2A (0.58) | ITGB3ITGAVITGA2BSLC7A5ALPI | |
| SCHEMBL19234474 | 0.87 | MITF (0.59) | ITGB3ITGAVITGA2BPTPN1TPH1 | |
| SCHEMBL19234475 | 0.87 | ITGB3 (0.57) | ITGB3ITGAVITGA2BSLC7A5ALPI | |
| SCHEMBL19234472 | 0.87 | ITGB3 (0.57) | ITGB3ITGAVITGA2BSLC7A5ALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615855-A2 | NEW ANTIBACTERIAL PRODUCTS | University of Liverpool (GB) | 2025-09-17 | — | — | EP | disclosed |
| WO-2024100391-A2 | NEW ANTIBACTERIAL PRODUCTS | UNIVERSITY OF LIVERPOOL (GB) | 2024-05-16 | — | — | WO | disclosed |
| EP-3578566-B1 | BIOCIDAL PEPTIDE AND PREPARATION BASED THEREON | VERTA RES PRODUCTION COMPANY LTD (RU) | 2023-07-19 | — | — | EP | disclosed |
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2022-04-14 | — | — | US | disclosed |
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2022-03-22 | — | — | US | disclosed |
| US-20190040102-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2019-02-07 | — | — | US | disclosed |
| WO-2017136943-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2017-08-17 | — | — | WO | disclosed |
| EP-1532262-B1 | PEPTIDE AMIDATION PROCESS | MEDTRONIC INC (US) | 2013-07-10 | — | — | EP | disclosed |
| US-8288130-B2 | Polypeptide cleavage process | MEDTRONIC, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-1532142-B1 | POLYPEPTIDE CLEAVAGE PROCESS | MEDTRONIC INC (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20050227313-A1 | Polypeptide cleavage process | MEDTRONIC, INC. | 2005-10-13 | — | — | US | disclosed |
| EP-1532142-A2 | POLYPEPTIDE CLEAVAGE PROCESS | Restoragen, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-1532262-A2 | PETIDE AMIDATION PROCESS | Restoragen, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-1531836-A2 | POLYPEPTIDE CLEAVAGE PROCESS | Restoragen, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004011599-A2 | POLYPEPTIDE CLEAVAGE PROCESS | RESTORAGEN, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| WO-2003099853-A2 | PETIDE AMIDATION PROCESS | RESTORAGEN, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003099852-A2 | PEPTIDE DERIVATIZATION PROCESS | RESTORAGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003100015-A2 | POLYPEPTIDE CLEAVAGE PROCESS | RESTORAGEN, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| JP-2001163802-A | 4-BENZOYLAMINOPHENYLALANINE DERIVATIVE | SANKYO CO LTD | 2001-06-19 | — | — | JP | disclosed |
| US-6197794-B1 | ANTIINFLAMAMTORY AGENTS; IMMUNOLOGY DISEASES | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | ITGB3 4181/4885ITGAV 4218/4885ITGA2B 4143/4885 |
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | GPR119, SSTR5, SSTR2 | ITGB3 4129/4885ITGAV 4173/4885ITGA2B 4089/4885 |
| US-20190040102-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | GPR119, SSTR5, SSTR2 | ITGB3 4181/4885ITGAV 4218/4885ITGA2B 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.